Results 351 to 360 of about 17,175,483 (375)
Some of the next articles are maybe not open access.
New England Journal of Medicine
AL Amyloidosis A 58-year-old man presented with a 2-year history of eyelid lesions and several months of weight loss and fatigue. Scattered periorbital petechiae and purpura were noted, as well as coalescing, waxy papules on the eyelids.
Mitsuharu Ueda
semanticscholar +5 more sources
AL Amyloidosis A 58-year-old man presented with a 2-year history of eyelid lesions and several months of weight loss and fatigue. Scattered periorbital petechiae and purpura were noted, as well as coalescing, waxy papules on the eyelids.
Mitsuharu Ueda
semanticscholar +5 more sources
Diagnosis and Treatment of AL Amyloidosis
Drugs, 2023Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. The heart and kidney are the major organs affected, but all others, with the exception of the CNS, can be involved. The disease is rapidly progressive, and it is still diagnosed late.
G. Palladini, P. Milani
semanticscholar +3 more sources
The Lancet, 2014 A 62-year-old man came to our outpatient clinic with purpura on his eyelids. 7 months before, periocular purpura appeared after a minimal trauma. These lesions did not resolve for months. He also reported fatigue over the previous 6 months. On examination pinch purpura between smooth waxy papules were found (fi gure).
Barbara C. Böckle, N Sepp
openaire +3 more sources
Etanercept AL amyloidosis [PDF]
The Lancet, 2001 Richard J. Powell, Elizabeth Drewe
openaire +3 more sources
Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation.
JCO Oncology Practice, 2023Despite significant progress and improving outcomes in the management of plasma cell disorders, AL amyloidosis remains diagnostically and therapeutically challenging for clinicians across practice settings.
D. Dima +6 more
semanticscholar +1 more source
American journal of hematology/oncology, 2022
High‐dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for selected patients with AL amyloidosis. We report the long‐term outcomes of 648 patients with AL amyloidosis treated with HDM/SCT over 25 years.
J. Gustine +14 more
semanticscholar +1 more source
High‐dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for selected patients with AL amyloidosis. We report the long‐term outcomes of 648 patients with AL amyloidosis treated with HDM/SCT over 25 years.
J. Gustine +14 more
semanticscholar +1 more source
Immunotherapy in AL Amyloidosis
Current Treatment Options in Oncology, 2022Light-chain amyloidosis is a rare disorder where a small clone of plasma cells is producing excess toxic light chains that deposit in various organs and cause dysfunction. Cardiac involvement is a major determinant of survival and rapid reduction of light chain is critical for recovery of organ function and overall survival. Immunotherapy targeting the
Yifei, Zhang, Raymond L, Comenzo
openaire +2 more sources
Once AL amyloidosis: not always AL amyloidosis
Amyloid, 2018Amyloid cardiomyopathy could be related to AL amyloidosis, wild-type transthyretin amyloidosis (ATTRwt) or hereditary amyloidosis (ATTRm).
Tulip Jhaveri +5 more
openaire +3 more sources
European Journal of Haematology, 2021
Light‐chain (AL) amyloidosis is a multisystem disorder with a high early mortality and diagnostic delays of >1 year from symptom onset. This retrospective observational study sought to characterize the clinical prodrome and diagnostic delay to inform ...
L. Hester +7 more
semanticscholar +1 more source
Light‐chain (AL) amyloidosis is a multisystem disorder with a high early mortality and diagnostic delays of >1 year from symptom onset. This retrospective observational study sought to characterize the clinical prodrome and diagnostic delay to inform ...
L. Hester +7 more
semanticscholar +1 more source